You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

CLINICAL TRIALS PROFILE FOR CLADRIBINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Cladribine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002805 ↗ Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 2 1997-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome in first relapse or who did not achieve first remission.
NCT00002805 ↗ Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed Children's Oncology Group Phase 2 1997-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome in first relapse or who did not achieve first remission.
NCT00002833 ↗ Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 2 1994-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002833 ↗ Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia Completed M.D. Anderson Cancer Center Phase 2 1994-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002879 ↗ Cladribine in Patients With Mantle Cell Lymphoma Completed National Cancer Institute (NCI) Phase 2 1996-11-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effects of cladribine in previously treated or untreated patients with mantle cell lymphoma.
NCT00002879 ↗ Cladribine in Patients With Mantle Cell Lymphoma Completed Alliance for Clinical Trials in Oncology Phase 2 1996-11-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effects of cladribine in previously treated or untreated patients with mantle cell lymphoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cladribine

Condition Name

Condition Name for Cladribine
Intervention Trials
Acute Myeloid Leukemia 25
Leukemia 18
Multiple Sclerosis 13
Lymphoma 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cladribine
Intervention Trials
Leukemia 76
Leukemia, Myeloid, Acute 51
Leukemia, Myeloid 51
Lymphoma 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cladribine

Trials by Country

Trials by Country for Cladribine
Location Trials
United States 238
China 38
Canada 18
Germany 16
Norway 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cladribine
Location Trials
Texas 21
Washington 16
New York 10
Maryland 10
California 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cladribine

Clinical Trial Phase

Clinical Trial Phase for Cladribine
Clinical Trial Phase Trials
Phase 4 11
Phase 3 16
Phase 2/Phase 3 7
[disabled in preview] 93
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cladribine
Clinical Trial Phase Trials
Recruiting 50
Completed 43
Unknown status 13
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cladribine

Sponsor Name

Sponsor Name for Cladribine
Sponsor Trials
National Cancer Institute (NCI) 33
M.D. Anderson Cancer Center 15
EMD Serono 8
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cladribine
Sponsor Trials
Other 192
Industry 46
NIH 34
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.